KR102671612B1 - 아릴아마이드 유도체의 제조 방법 - Google Patents
아릴아마이드 유도체의 제조 방법 Download PDFInfo
- Publication number
- KR102671612B1 KR102671612B1 KR1020237036428A KR20237036428A KR102671612B1 KR 102671612 B1 KR102671612 B1 KR 102671612B1 KR 1020237036428 A KR1020237036428 A KR 1020237036428A KR 20237036428 A KR20237036428 A KR 20237036428A KR 102671612 B1 KR102671612 B1 KR 102671612B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- methyl
- mmol
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021120977 | 2021-07-21 | ||
| JPJP-P-2021-120977 | 2021-07-21 | ||
| PCT/JP2022/028187 WO2023003014A1 (ja) | 2021-07-21 | 2022-07-20 | アリールアミド誘導体の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230152797A KR20230152797A (ko) | 2023-11-03 |
| KR102671612B1 true KR102671612B1 (ko) | 2024-05-31 |
Family
ID=84980009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237036428A Active KR102671612B1 (ko) | 2021-07-21 | 2022-07-20 | 아릴아마이드 유도체의 제조 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240327355A1 (enExample) |
| EP (1) | EP4375273A4 (enExample) |
| JP (2) | JP7268255B1 (enExample) |
| KR (1) | KR102671612B1 (enExample) |
| CN (1) | CN117677607A (enExample) |
| AR (1) | AR126517A1 (enExample) |
| AU (1) | AU2022312992A1 (enExample) |
| CA (1) | CA3226827A1 (enExample) |
| IL (1) | IL310123A (enExample) |
| MX (1) | MX2024000908A (enExample) |
| TW (1) | TW202321198A (enExample) |
| WO (1) | WO2023003014A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025007811A1 (zh) * | 2023-07-06 | 2025-01-09 | 成都华健未来科技有限公司 | 一类芳香酰胺类衍生物及其用途 |
| WO2025146040A1 (zh) * | 2024-01-01 | 2025-07-10 | 华健未来（成都）科技股份有限公司 | 芳香酰肼类衍生物及其医药用途 |
| CN118604164B (zh) * | 2024-05-15 | 2025-06-06 | 石家庄四药有限公司 | 一种非奈利酮中间体中杂质的检测方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200520745A (en) * | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| JP2016034900A (ja) * | 2012-11-26 | 2016-03-17 | 中外製薬株式会社 | ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法 |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| JPWO2022018875A1 (enExample) * | 2020-07-22 | 2022-01-27 | ||
| BR112023000883A2 (pt) * | 2020-07-22 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Composição contendo derivado de arilamida |
-
2022
- 2022-07-20 WO PCT/JP2022/028187 patent/WO2023003014A1/ja not_active Ceased
- 2022-07-20 CA CA3226827A patent/CA3226827A1/en active Pending
- 2022-07-20 US US18/579,949 patent/US20240327355A1/en active Pending
- 2022-07-20 MX MX2024000908A patent/MX2024000908A/es unknown
- 2022-07-20 IL IL310123A patent/IL310123A/en unknown
- 2022-07-20 CN CN202280050524.4A patent/CN117677607A/zh active Pending
- 2022-07-20 EP EP22845947.5A patent/EP4375273A4/en active Pending
- 2022-07-20 AU AU2022312992A patent/AU2022312992A1/en active Pending
- 2022-07-20 TW TW111127162A patent/TW202321198A/zh unknown
- 2022-07-20 KR KR1020237036428A patent/KR102671612B1/ko active Active
- 2022-07-20 AR ARP220101914A patent/AR126517A1/es unknown
- 2022-07-20 JP JP2022563493A patent/JP7268255B1/ja active Active
-
2023
- 2023-04-20 JP JP2023069597A patent/JP2023084138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL310123A (en) | 2024-03-01 |
| AU2022312992A1 (en) | 2024-02-29 |
| JP2023084138A (ja) | 2023-06-16 |
| US20240327355A1 (en) | 2024-10-03 |
| CN117677607A (zh) | 2024-03-08 |
| JPWO2023003014A1 (enExample) | 2023-01-26 |
| MX2024000908A (es) | 2024-02-07 |
| KR20230152797A (ko) | 2023-11-03 |
| TW202321198A (zh) | 2023-06-01 |
| CA3226827A1 (en) | 2023-01-26 |
| AR126517A1 (es) | 2023-10-18 |
| EP4375273A1 (en) | 2024-05-29 |
| WO2023003014A1 (ja) | 2023-01-26 |
| EP4375273A4 (en) | 2025-05-21 |
| JP7268255B1 (ja) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI788763B (zh) | 具有抗腫瘤活性之芳醯胺衍生物 | |
| KR102671612B1 (ko) | 아릴아마이드 유도체의 제조 방법 | |
| TWI871397B (zh) | Ｋｒａｓ突變蛋白抑制劑 | |
| KR102566299B1 (ko) | 아릴 아마이드 유도체를 포함하는 조성물 | |
| KR102550455B1 (ko) | 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물 | |
| EP3889150A1 (en) | Compound serving as irak inhibitor | |
| WO2020011209A1 (zh) | 免疫抑制剂及其制备方法和在药学上的应用 | |
| KR102866724B1 (ko) | 아자헤테로아릴 화합물 및 이의 용도 | |
| CN113825751A (zh) | 一种阻断pd-1/pd-l1相互作用的联苯基衍生物及其制备方法和应用 | |
| KR102904379B1 (ko) | 항종양 활성을 갖는 아릴 아마이드 유도체 | |
| WO2024199524A1 (zh) | 作为pkmyt1抑制剂的化合物 | |
| HK40073328A (en) | Arylamide derivative having antitumor activity | |
| HK40073328B (zh) | 具有抗肿瘤活性的芳基醯胺衍生物 | |
| TWI904197B (zh) | 含有芳醯胺衍生物的組合物 | |
| HK40084009B (zh) | 包含芳基酰胺衍生物的组合物 | |
| WO2025209520A1 (zh) | 一种化合物、包含其的药物组合物及其用途 | |
| CN116987083A (zh) | 吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途 | |
| EA050002B1 (ru) | Способ получения производного ариламида | |
| EA047579B1 (ru) | Производное ариламида, обладающее противоопухолевой активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A302 | Request for accelerated examination | ||
| PA0105 | International application |
Patent event date: 20231024 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20231024 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240304 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240529 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240529 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |